<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="2" iati-activities:version="2.03" xml:lang="EN" xmlns:gavi="http://gavi.org/" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>47122-LKA-HPV</iati-identifier>
  <reporting-org ref="47122" type="40">
   <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Sri Lanka: Human Papillomavirus</narrative>
   <narrative xml:lang="FR">Sri Lanka: Papillomavirus humain</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">GAVI&#x2019;s support for new vaccines presents an opportunity for countries to not only implement vaccines that protect against diseases causing substantial morbidity and/or mortality, but also to build upon the vaccine investments in order to increase immunisation coverage rates, and strengthen routine immunisation services and primary health care systems. In line with a 2009 WHO position paper on cervical cancer recommending that routine human papillomavirus (HPV) vaccination be included in national immunisation programmes, GAVI provides support to eligible countries for HPV vaccines that protect against types 16 and 18, responsible for causing about 70% of cervical cancer cases. The form of support provided by GAVI depends on the level of demonstrated ability in a country to deliver vaccines to young adolescent girls. Countries that have demonstrated the ability may apply for GAVI support for nationwide introduction of HPV vaccines.</narrative>
   <narrative xml:lang="FR">Gavi soutient l&#x2019;introduction du vaccin anti-VPH &#xE0; l&#x2019;&#xE9;chelon national et la vaccination de multiples cohortes de jeunes filles &#xE2;g&#xE9;es de 9 &#xE0; 14 ans. La meilleure strat&#xE9;gie pour r&#xE9;duire rapidement la charge de morbidit&#xE9; du cancer du col de l&#x2019;ut&#xE9;rus consiste &#xE0; associer la vaccination au d&#xE9;pistage et aux soins. Mais le co&#xFB;t &#xE9;lev&#xE9; de ce vaccin et la difficult&#xE9; &#xE0; mettre en place des structures permettant de toucher les adolescentes freinaient son introduction par les pays &#xE0; faible revenu. Gavi y rem&#xE9;die en fournissant ce vaccin durablement &#xE0; des prix et abordables, et en accompagnant les pays dans le lancement de programmes pilotes, permettant de tester les diff&#xE9;rents moyens de l&#x2019;administrer aux adolescentes. L&#x2019;OMS recommande aux pays d&#x2019;administrer ce vaccin en tenant compte de la compatibilit&#xE9; entre les strat&#xE9;gies adopt&#xE9;es et les infrastructures de sant&#xE9; nationales, en s&#x2019;assurant que les strat&#xE9;gies sont abordables, rentables et p&#xE9;rennes, et permettent d&#x2019;atteindre la couverture la plus &#xE9;lev&#xE9;e possible. Les pays doivent accorder la priorit&#xE9; aux populations susceptibles de ne pas avoir acc&#xE8;s au d&#xE9;pistage du cancer du col de l&#x2019;ut&#xE9;rus et associer la prestation de la vaccination &#xE0; d&#x2019;autres programmes ciblant les adolescentes.
L&#x2019;engagement de Gavi &#xE0; prot&#xE9;ger les femmes contre le cancer du col de l&#x2019;ut&#xE9;rus appuie l&#x2019;initiative mondiale du Secr&#xE9;taire g&#xE9;n&#xE9;ral de l&#x2019;ONU pour la sant&#xE9; des femmes et des enfants &#xE0; r&#xE9;pondre aux grandes priorit&#xE9;s de sant&#xE9; mondiale en am&#xE9;liorant l&#x2019;acc&#xE8;s aux vaccins salvateurs.</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="FR">Cette activit&#xE9; d&#xE9;taille notre travail sur le Papillomavirus humain en Sri Lanka, gr&#xE2;ce &#xE0; la mise &#xE0; disposition des donn&#xE9;es budg&#xE9;taires et des transactions. Nous fournissons &#xE9;galement les documents pertinents qui guident ces activit&#xE9;s que sont les formulaires de demande de soutien fournis par le gouvernement de Sri Lanka ainsi que les lettres de d&#xE9;cisions &#xE9;mises par Gavi, pour progresser. Ces documents d&#xE9;crivent les activit&#xE9;s, les objectifs ainsi que les b&#xE9;n&#xE9;ficiaires.</narrative>
   <narrative xml:lang="EN">This activity details our work on Human Papillomavirus in Sri Lanka through the provision of budget and transaction data.  We also provide the relevant documents that guide these activities, which are the support request proposal(s) provided by the Government of Sri Lanka, as well as the decision letter(s) issued by Gavi, for progress.  These documents describe the activities, the objectives as well as the beneficiaries.</narrative>
  </description>
  <participating-org ref="47122" role="1" type="40">
   <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
  </participating-org>
  <participating-org ref="47122" role="3" type="40">
   <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
  </participating-org>
  <participating-org role="4">
   <narrative xml:lang="EN">Ministry of Health, Sri Lanka</narrative>
  </participating-org>
  <participating-org role="4" type="10">
   <narrative xml:lang="EN">The Government of Sri Lanka</narrative>
  </participating-org>
  <participating-org ref="XM-DAC-41122" role="4" type="40">
   <narrative xml:lang="EN">UNICEF Supply Division</narrative>
  </participating-org>
  <other-identifier ref="47122" type="B1">
   <owner-org ref="47122">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </owner-org>
  </other-identifier>
  <other-identifier ref="47122-17-LKA-08F-Y" type="A3"></other-identifier>
  <other-identifier ref="47122-17-LKA-19B-X" type="A3"></other-identifier>
  <activity-status code="3"></activity-status>
  <activity-date iso-date="2017-01-01" type="1"></activity-date>
  <activity-date iso-date="2017-01-01" type="2"></activity-date>
  <activity-date iso-date="2017-12-31" type="3"></activity-date>
  <activity-date iso-date="2017-12-31" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </organisation>
   <email>info@gavi.org</email>
   <website>http://www.gavi.org/</website>
  </contact-info>
  <activity-scope code="4"></activity-scope>
  <recipient-country code="LK" percentage="100"></recipient-country>
  <location>
   <location-reach code="1"></location-reach>
   <location-id code="LK" vocabulary="A4"></location-id>
   <name>
    <narrative xml:lang="EN">Colombo</narrative>
   </name>
   <administrative code="LK" vocabulary="A4"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>6.93194 79.84778</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="2"></location-class>
  </location>
  <sector code="HPV" percentage="100" vocabulary="99">
   <narrative xml:lang="EN">Human Papillomavirus</narrative>
  </sector>
  <sector code="12250" percentage="100" vocabulary="1"></sector>
  <tag code="1" vocabulary="2"></tag>
  <tag code="10" vocabulary="2"></tag>
  <tag code="11" vocabulary="2"></tag>
  <tag code="13" vocabulary="2"></tag>
  <tag code="16" vocabulary="2"></tag>
  <tag code="17" vocabulary="2"></tag>
  <tag code="2" vocabulary="2"></tag>
  <tag code="3" vocabulary="2"></tag>
  <tag code="4" vocabulary="2"></tag>
  <tag code="5" vocabulary="2"></tag>
  <tag code="7" vocabulary="2"></tag>
  <tag code="8" vocabulary="2"></tag>
  <tag code="9" vocabulary="2"></tag>
  <policy-marker code="1" significance="2" vocabulary="1"></policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1"></policy-marker>
  <collaboration-type code="2"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="2" type="2">
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-31"></period-end>
   <value currency="USD" value-date="2022-06-09">1463357.3</value>
  </budget>
  <capital-spend percentage="0"></capital-spend>
  <transaction ref="LKAHPV2017">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-01-01"></transaction-date>
   <value currency="USD" value-date="2017-01-01">1463357.3</value>
   <description>
    <narrative xml:lang="EN">Approved 2017 budget for Sri Lanka HPV</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org type="10">
    <narrative xml:lang="EN">The Government of Sri Lanka</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-04-25"></transaction-date>
   <value currency="USD" value-date="2017-04-25">417000</value>
   <description>
    <narrative xml:lang="EN">Cash disbursement for programme LKA-HPV-R-VIG-MOH</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">Ministry of Health, Sri Lanka</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-05-18"></transaction-date>
   <value currency="USD" value-date="2017-05-18">1042250</value>
   <description>
    <narrative xml:lang="EN">Vaccine disbursement for programme LKA-HPV-R-VAC</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XM-DAC-41122" type="40">
    <narrative xml:lang="EN">UNICEF Supply Division</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-11-30"></transaction-date>
   <value currency="USD" value-date="2017-11-30">4107.3</value>
   <description>
    <narrative xml:lang="EN">Vaccine disbursement for programme LKA-HPV-R-VAC</narrative>
   </description>
   <provider-org ref="47122" type="40">
    <narrative xml:lang="EN">Gavi, The Vaccine Alliance</narrative>
   </provider-org>
   <receiver-org ref="XM-DAC-41122" type="40">
    <narrative xml:lang="EN">UNICEF Supply Division</narrative>
   </receiver-org>
  </transaction>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/fr/actualites/librarie-de-documents/proposal-nvs-hpv-support-sri-lanka">
   <title>
    <narrative xml:lang="EN">Proposal for NVS - HPV support: Sri Lanka</narrative>
   </title>
   <category code="A01"></category>
   <category code="A02"></category>
   <category code="A03"></category>
   <category code="A09"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/news/document-library/proposal-nvs-hpv-support-sri-lanka">
   <title>
    <narrative xml:lang="EN">Proposal for NVS - HPV support: Sri Lanka</narrative>
   </title>
   <category code="A01"></category>
   <category code="A02"></category>
   <category code="A03"></category>
   <category code="A09"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://www.gavi.org/types-support/vaccine-support/human-papillomavirus">
   <title>
    <narrative xml:lang="EN">Human papillomavirus vaccine support &amp; Gavi&#x2019;s impact</narrative>
   </title>
   <category code="A02"></category>
   <category code="A03"></category>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://www.gavi.org/fr/types-de-soutien/vaccins/papillomavirus-humain">
   <title>
    <narrative xml:lang="EN">Soutien au vaccin contre le papillomavirus humain &amp; l&apos;action de Gavi</narrative>
   </title>
   <category code="A02"></category>
   <category code="A03"></category>
   <category code="A12"></category>
   <language code="FR"></language>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/fr/actualites/librarie-de-documents/decision-letter-nvs-sri-lanka-2017">
   <title>
    <narrative xml:lang="EN">Decision Letter NVS Sri Lanka 2017</narrative>
   </title>
   <category code="A04"></category>
   <category code="A05"></category>
   <category code="A06"></category>
   <category code="A09"></category>
   <category code="A11"></category>
   <language code="EN"></language>
   <document-date iso-date="2017-12-31"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.gavi.org/news/document-library/decision-letter-nvs-sri-lanka-2017">
   <title>
    <narrative xml:lang="EN">Decision Letter NVS Sri Lanka 2017</narrative>
   </title>
   <category code="A04"></category>
   <category code="A05"></category>
   <category code="A06"></category>
   <category code="A09"></category>
   <category code="A11"></category>
   <language code="EN"></language>
   <document-date iso-date="2017-12-31"></document-date>
  </document-link>
  <related-activity ref="47122-LKA" type="1"></related-activity>
  <conditions attached="1">
   <condition type="3">
    <narrative xml:lang="EN">Conditions are available in the decision letters</narrative>
   </condition>
  </conditions>
  <result type="1">
   <title>
    <narrative xml:lang="EN">Sri Lanka: Human Papillomavirus</narrative>
   </title>
   <indicator ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">HPV 1 Coverage among females</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">Target is population</narrative>
    </description>
    <period>
     <period-start iso-date="2017-01-01"></period-start>
     <period-end iso-date="2017-12-31"></period-end>
     <target value="173317">
      <location ref="LK"></location>
     </target>
     <actual value="117071">
      <location ref="LK"></location>
     </actual>
    </period>
    <period>
     <period-start iso-date="2020-01-01"></period-start>
     <period-end iso-date="2020-12-31"></period-end>
     <target value="170338">
      <location ref="LK"></location>
     </target>
     <actual value="119977">
      <location ref="LK"></location>
     </actual>
    </period>
    <period>
     <period-start iso-date="2019-01-01"></period-start>
     <period-end iso-date="2019-12-31"></period-end>
     <target value="173130">
      <location ref="LK"></location>
     </target>
     <actual value="172054">
      <location ref="LK"></location>
     </actual>
    </period>
    <period>
     <period-start iso-date="2018-01-01"></period-start>
     <period-end iso-date="2018-12-31"></period-end>
     <target value="345831">
      <location ref="LK"></location>
     </target>
     <actual value="300809">
      <location ref="LK"></location>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">HPV Last Coverage among females</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">Target is population</narrative>
    </description>
    <period>
     <period-start iso-date="2019-01-01"></period-start>
     <period-end iso-date="2019-12-31"></period-end>
     <target value="173130">
      <location ref="LK"></location>
     </target>
     <actual value="142761">
      <location ref="LK"></location>
     </actual>
    </period>
    <period>
     <period-start iso-date="2018-01-01"></period-start>
     <period-end iso-date="2018-12-31"></period-end>
     <target value="345831">
      <location ref="LK"></location>
     </target>
     <actual value="199579">
      <location ref="LK"></location>
     </actual>
    </period>
    <period>
     <period-start iso-date="2020-01-01"></period-start>
     <period-end iso-date="2020-12-31"></period-end>
     <target value="170338">
      <location ref="LK"></location>
     </target>
     <actual value="87420">
      <location ref="LK"></location>
     </actual>
    </period>
   </indicator>
  </result>
 </iati-activity>
</iati-activities>
